Sanofi's pharmaceutical dominance faces a critical juncture as the board orchestrates an urgent leadership reshuffle, bringing in a Merck executive to tackle the company's paralyzed innovation pipeline. The French giant's substantial R&D investments have yet to yield meaningful breakthroughs, marking what investors view as a death knell for the firm's previous strategic direction. This leadership overhaul signals that patience with the current trajectory has evaporated. Market sentiment turned sharply negative, with the stock plummeting over 6% in pre-market trading—a stark reflection of investor concerns that the innovation crisis could severely impact future competitiveness. The incoming executive faces mounting pressure to reverse course on the R&D front and restore confidence in Sanofi's pipeline revival strategy.